rethinkTHC Search
Menu
Study breakdown

How the endocannabinoid system may drive fibromyalgia symptoms

Narrative ReviewPreliminary evidence
The takeaway

A review of emerging evidence suggests that dysregulation of the endocannabinoid system may contribute to the widespread pain, fatigue, and cognitive difficulties characteristic of fibromyalgia.

Fibromyalgia patients, pain researchers, and clinicians exploring cannabinoid-based approaches to chronic pain conditions.

What the researchers found

The endocannabinoid system plays a central role in pain perception, mood regulation, and inflammation, and variations in endocannabinoid levels and receptor activity in fibromyalgia patients may contribute to clinical symptoms.

Why it matters

Fibromyalgia affects millions and remains poorly understood with limited treatment options. If endocannabinoid system dysfunction is a key driver, it could open pathways for targeted cannabinoid-based therapies.

The numbers in context

No specific numerical outcomes reported; this is a qualitative synthesis of existing literature.

How the study worked

Narrative review analyzing published literature on the endocannabinoid system's involvement in fibromyalgia pathophysiology, with a focus on pain modulation mechanisms.

What this study cannot tell us

Narrative review rather than systematic review, so subject to selection bias. Much of the evidence on ECS dysfunction in fibromyalgia is indirect or from small studies.

How to read the evidence

Narrative review synthesizing mostly preliminary evidence from small studies and indirect observations.

When this study was published

2025 publication.

The bigger picture

The "clinical endocannabinoid deficiency" hypothesis has been proposed as an explanation for fibromyalgia, migraines, and irritable bowel syndrome. This review gathers the evidence supporting that theory for fibromyalgia.

Questions still open

  • Can endocannabinoid levels serve as biomarkers for fibromyalgia diagnosis or treatment response?
  • Would cannabinoid therapies targeting specific ECS components outperform current fibromyalgia treatments?

Common questions

What is the endocannabinoid deficiency theory?
The theory proposes that some chronic conditions like fibromyalgia, migraines, and IBS may result from insufficient endocannabinoid signaling. If the body does not produce enough endocannabinoids or has altered receptor function, pain and other symptoms may become amplified.
Does this mean cannabis treats fibromyalgia?
The review examines mechanisms, not treatment outcomes. Clinical trials are needed to test specific interventions.

Read the original research

Role of the Endocannabinoid System in Fibromyalgia.

Current issues in molecular biology, 47(4)

Citation

García-Domínguez, Mario. (2025). Role of the Endocannabinoid System in Fibromyalgia.. Current issues in molecular biology, 47(4). https://doi.org/10.3390/cimb47040230

Explore the wider topic